More recently, CD39 has been identified as a marker for tumor-specific CD4+ T cell population in human TILs suggesting that CD39 could be used to identify, isolate and expand tumor-reactive T cell population before ACT immunotherapy [183]. Here, ENTPD1 is linked to neoplasm.